62766 Federal Register / Vol. 75, No. 197 / Wednesday, October 13, 2010 / Notices 

antidumping duties of 58.90 percent, 

the weighted-average percentage 

dumping margin we found for Alpanil 

Industries in the most recently 

completed review. See Carbazole Violet 

Pigment 23 From India: Final Results of 

Antidumping Duty Administrative 

Review, 75 FR 38076 (July 1, 2010). 

Notification 

This notice serves as a reminder to 

parties subject to the administrative 

protective order (APO) of their 

responsibility concerning the 

disposition of proprietary information 

disclosed under APO in accordance 

with 19 CFR 351.306. Timely written 

notification of the destruction of APO 

materials or conversion to judicial 

protective order is hereby requested. 

Failure to comply with the regulations 

and terms of an APO is a sanctionable 

violation. 

This notice is published in 

accordance with sections 751(b)(1) and 

777(i) of the Act and 19 CFR 351.216 

and 19 CFR 351.221. 

Dated: October 6, 2010. 

Ronald K. Lorentzen, 

Deputy Assistant Secretary for Import 

Administration. 

[FR Doc. 2010–25777 Filed 10–12–10; 8:45 am] 

BILLING CODE 3510–DS–P 

DEPARTMENT OF COMMERCE 

International Trade Administration 

[A–570–908] 

First Antidumping Duty Administrative 

Review of Sodium Hexametaphosphate 

From the People’s Republic of China: 

Extension of Time Limit for the Final 

Results 

AGENCY: Import Administration, 

International Trade Administration, 

Department of Commerce 

DATES: Effective Date: October 13, 2010. 

FOR FURTHER INFORMATION CONTACT: Paul 

Walker, AD/CVD Operations, Office 9, 

Import Administration, International 

Trade Administration, U.S. Department 

of Commerce, 14th Street and 

Constitution Avenue, NW., Washington, 

DC 20230; telephone: (202) 482–0413. 

Background 

On April 15, 2010 the Department of 

Commerce (‘‘Department’’) published the 

Preliminary Results of the first 

administrative review of sodium 

hexametaphosphate From the People’s 

Republic of China (‘‘PRC’’), covering the 

period September 14, 2007 through 

February 28, 2009. See First 

Administrative Review of Sodium 

Hexametaphosphate From the People’s 

Republic of China: Notice of Preliminary 

Results of the Antidumping Duty 

Administrative Review, 75 FR 19613 

(April 15, 2010) (‘‘Preliminary Results’’). 

On August 10, 2010 the Department 

extended the final results of review to 

October 5, 2010. See First Antidumping 

Duty Administrative Review of Sodium 

Hexametaphosphate From the People’s 

Republic of China: Extension of Time 

Limit for the Final Results, 75 FR 48309 

(August 10, 2010). 

Extension of Time Limit for the 

Preliminary Results 

As noted in the August 10 extension 

notice, section 751(a)(3)(A) of the Tariff 

Act of 1930, as amended (‘‘the Act’’), 

requires the Department to issue the 

final results of an administrative review 

within 120 days after the date on which 

the Preliminary Results have been 

published. If it is not practicable to 

complete the review within the time 

period, section 751(a)(3)(A) of the Act 

allows the Department to extend this 

deadline to a maximum of 180 days. 

The Department determines that 

completion of the final results of this 

review by the current deadline is not 

practicable. The Department requires 

more time to analyze a significant 

amount of information pertaining to the 

respondent’s corporate structure and 

ownership, sales practices and 

manufacturing methods. Therefore, 

given the number and complexity of 

issues in this case, and in accordance 

with section 751(a)(3)(A) of the Act, we 

are extending the time period for issuing 

the final results of review until October 

12, 2010. 

This notice is published pursuant to 

sections 751(1)(3)(A) and 777(i)(1) of the 

Act and 19 CFR 351.213(h)(2). 

Dated: October 5, 2010. 

Susan H. Kuhbach, 

Acting Deputy Assistant Secretary for 

Antidumping and Countervailing Duty 

Operations. 

[FR Doc. 2010–25770 Filed 10–12–10; 8:45 am] 

BILLING CODE 3510–DS–P 

DEPARTMENT OF COMMERCE 

United States Patent and Trademark 

Office 

[Docket No. PTO–P–2010–0079] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,407,914; 

SURFAXIN® (Lucinactant) 

AGENCY: United States Patent and 

Trademark Office. 

ACTION: Notice of Interim Patent Term 

Extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a second one-year 

interim extension of the term of U.S. 

Patent No. 5,407,914. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755, or by e-mail to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On September 22, 2010, Discovery 

Laboratories Inc., on behalf of patent 

owner Scripps Research Institute, timely 

filed an application under 35 U.S.C. 

156(d)(5) for an additional interim 

extension of the term of U.S. Patent No. 

5,407,914. The patent claims the human 

drug product, SURFAXIN® (lucinactant) 

and a method of using SURFAXIN®

(lucinactant). The application indicates 

that a New Drug Application, NDA No. 

21–746, for the human drug product 

SURFAXIN® (lucinactant) has been 

filed, and is currently undergoing 

regulatory review before the Food and 

Drug Administration for permission to 

market or use the product commercially. 

Review of the application indicates 

that except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for an additional one year 

as required by 35 U.S.C. 156(d)(5)(B). 

Because it is apparent that the 

regulatory review period will continue 

beyond the extended expiration date of 

the patent, November 17, 2010, interim 

extension of the patent term under 35 

U.S.C. 156(d)(5) is appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,407,914 is granted for a period of one 

additional year from the extended 

expiration date of the patent, i.e., until 

November 17, 2011. 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 197 / Wednesday, October 13, 2010 / Notices 62767 

Dated: October 7, 2010. 

Robert W. Bahr, 

Acting Associate Commissioner for Patent 

Examination Policy, United States Patent and 

Trademark Office. 

[FR Doc. 2010–25768 Filed 10–12–10; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF COMMERCE 

United States Patent and Trademark 

Office 

[Docket No. PTO–P–PTO–P–2010–0081] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 4,919,140; AndaraTM

OFSTM System 

AGENCY: United States Patent and 

Trademark Office. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a third one-year 

interim extension of the term of U.S. 

Patent No. 4,919,140. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755, or by e-mail to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On September 13, 2010, the patent 

owner, Purdue Research Foundation, 

timely filed an application under 35 

U.S.C. 156(d)(5) for a third interim 

extension of the term of U.S. Patent No. 

4,919,140. The patent claims the 

medical device AndaraTM OFSTM

System and a method of using the 

AndaraTM OFSTM System. The 

application indicates that a 

Humanitarian Device Exemption, HDE 

070002, for the medical device 

AndaraTM OFSTM System has been filed 

and is currently undergoing regulatory 

review before the Food and Drug 

Administration for permission to market 

or use the product commercially. 

Review of the application indicates 

that except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for an additional one year 

as required by 35 U.S.C. 156(d)(5)(B). 

Because it is apparent that the 

regulatory review period will continue 

beyond the extended expiration date of 

the patent (October 14, 2010), interim 

extension of the patent term under 35 

U.S.C. 156(d)(5) is appropriate. 

A third interim extension under 35 

U.S.C. 156(d)(5) of the term of U.S. 

Patent No. 4,919,140 is granted for a 

period of one year from the extended 

expiration date of the patent, i.e., until 

October 14, 2011. 

Dated: October 7, 2010. 

Robert W. Bahr, 

Acting Associate Commissioner for Patent 

Examination Policy, United States Patent and 

Trademark Office. 

[FR Doc. 2010–25767 Filed 10–12–10; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF DEFENSE 

Office of the Secretary 

[Transmittal Nos. 10–53, 10–54, 10–55, 10– 

59, 10–60, 10–61, and 10–63] 

36(b)(1) Arms Sales Notifications 

AGENCY: Defense Security Cooperation 

Agency, DoD. 

ACTION: Notice. 

SUMMARY: The Department of Defense is 

publishing the unclassified text of seven 

section 36(b)(1) arms sales notifications 

to fulfill the requirements of section 155 

of Public Law 104–164, dated 21 July 

1996. 

FOR FURTHER INFORMATION CONTACT: Ms. 

B. English, DSCA/DBO/CFM, (703) 601– 

3740. 

SUPPLEMENTARY INFORMATION: The 

following are copies of letters to the 

Speaker of the House of Representatives, 

Transmittals 10–53, 10–54, 10–55, 10– 

59, 10–60, 10–61, and 10–63 with 

associated attachments. 

Dated: October 6, 2010. 

Mitchell S. Bryman, 

Alternate OSD Federal Register Liaison 

Officer, Department of Defense. 

Transmittal No. 10–53 

The following is a copy of a letter to 

the Speaker of the House of 

Representatives, Transmittal 10–53 with 

attached transmittal and policy 

justification. 

BILLING CODE 5001–06–P 

mstockstill on DSKH9S0YB1PROD with NOTICES